Presentation Title

Synthesis of Copper(II) Complexes with Potential for Antitumor Activity

Start Date

November 2016

End Date

November 2016

Location

HUB 268

Type of Presentation

Oral Talk

Abstract

The harmful side effects associated with the chemotherapeutic Cisplatin (cisdiamminedichloroplatinum(II)) have motivated research for drugs based on other transition metals, including Copper(II). In an effort to expand the library of Copper(II) based anticancer drugs, bis complexes containing bipyridine (bipy) derivatives as ligands have been synthesized and characterized. All reactions were completed by adding appropriate equivalents of each ligand to a copper(II) ion. [(4,4’dimethylbipy)2Cu](NO3)2 and [(6,6’dimethylbipy)2Cu](NO3)2 were successfully made by reacting Cu(NO3)2*2.5H2O with two equivalents of the appropriate ligand in methanol at 50oC. These characterizations are supported by X-ray crystallography and elemental analysis, which indicate that a pure product was formed for both reactions. [(4,4’dimethylbipy)2Cu]ClBF4 and [(6,6’dimethylbipy)2Cu]ClBF4 were successfully made by reacting [(4,4’dimethylbipy)Cu]Cl2 and [(6,6’dimethylbipy)Cu]Cl2 with AgBF4 and one equivalent of appropriate ligand in acetonitrile at 50oC. These compounds are likewise confirmed by elemental analysis. The presence of an additional ligand on the synthesized complexes will likely stabilize the interaction between the complex and DNA, potentially enhancing the cytotoxicity of these bis complexes compared to their mono counterparts. Future work will test the in vitro antitumor activity of the reported compounds against glioblastoma brain cancer cells, along with redox stability and quantitative DNA binding of these copper complexes.

This document is currently not available here.

Share

COinS
 
Nov 12th, 3:00 PM Nov 12th, 3:15 PM

Synthesis of Copper(II) Complexes with Potential for Antitumor Activity

HUB 268

The harmful side effects associated with the chemotherapeutic Cisplatin (cisdiamminedichloroplatinum(II)) have motivated research for drugs based on other transition metals, including Copper(II). In an effort to expand the library of Copper(II) based anticancer drugs, bis complexes containing bipyridine (bipy) derivatives as ligands have been synthesized and characterized. All reactions were completed by adding appropriate equivalents of each ligand to a copper(II) ion. [(4,4’dimethylbipy)2Cu](NO3)2 and [(6,6’dimethylbipy)2Cu](NO3)2 were successfully made by reacting Cu(NO3)2*2.5H2O with two equivalents of the appropriate ligand in methanol at 50oC. These characterizations are supported by X-ray crystallography and elemental analysis, which indicate that a pure product was formed for both reactions. [(4,4’dimethylbipy)2Cu]ClBF4 and [(6,6’dimethylbipy)2Cu]ClBF4 were successfully made by reacting [(4,4’dimethylbipy)Cu]Cl2 and [(6,6’dimethylbipy)Cu]Cl2 with AgBF4 and one equivalent of appropriate ligand in acetonitrile at 50oC. These compounds are likewise confirmed by elemental analysis. The presence of an additional ligand on the synthesized complexes will likely stabilize the interaction between the complex and DNA, potentially enhancing the cytotoxicity of these bis complexes compared to their mono counterparts. Future work will test the in vitro antitumor activity of the reported compounds against glioblastoma brain cancer cells, along with redox stability and quantitative DNA binding of these copper complexes.